• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Merck Commits to Veeva Vault CRM

    7/21/25 10:00:00 AM ET
    $MRK
    $VEEV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology
    Get the next $MRK alert in real time by email

    Deep application provides foundation for commercial execution

    PLEASANTON, Calif., July 21, 2025 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) today announced that Merck (NYSE:MRK), known as MSD outside of the United States and Canada, has committed to Veeva Vault CRM.

    Veeva Systems (PRNewsfoto/Veeva Systems)

    The Vault CRM solution will support Merck as they enter one of the most significant launch periods in the company's history across a diverse set of new therapeutic areas and modalities.

    "We are excited to expand our strategic partnership with Veeva by moving to Vault CRM," said Dave Williams, executive vice president and chief information and digital officer at Merck. "We share a deep commitment to customer success, and Vault CRM will provide Merck the technology foundation to drive commercial execution."

    "Merck has consistently been at the forefront of leading-edge science that improves the lives of millions around the world," said Veeva CEO Peter Gassner. "We are honored to be a strategic partner to Merck and it is great to see our partnership extend to Vault CRM."

    Vault CRM is part of the Vault CRM Suite of deep applications that drive more effective commercial execution across personal and digital channels. With advanced global capabilities, Vault CRM Suite addresses the industry's unique regional and country-specific business and compliance requirements. 

    About Veeva Systems

    Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

    Contact:

     



    Maria Scurry

    Veeva Systems

    [email protected]

    Meera Lakhani-Patel

    Veeva Europe

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/merck-commits-to-veeva-vault-crm-302509227.html

    SOURCE Veeva Systems

    Get the next $MRK alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MRK
    $VEEV

    CompanyDatePrice TargetRatingAnalyst
    Veeva Systems Inc.
    $VEEV
    5/29/2025$270.00 → $300.00Buy
    Needham
    Merck & Company Inc.
    $MRK
    5/14/2025$84.00Buy → Neutral
    Citigroup
    Merck & Company Inc.
    $MRK
    4/22/2025$85.00Neutral
    Cantor Fitzgerald
    Merck & Company Inc.
    $MRK
    2/18/2025$128.00 → $105.00Buy → Hold
    Deutsche Bank
    Merck & Company Inc.
    $MRK
    2/10/2025$121.00 → $100.00Buy → Hold
    TD Cowen
    Veeva Systems Inc.
    $VEEV
    1/23/2025$261.00 → $200.00Buy → Sell
    Goldman
    Merck & Company Inc.
    $MRK
    1/8/2025$110.00Buy → Hold
    Truist
    Veeva Systems Inc.
    $VEEV
    12/20/2024$280.00Overweight
    Stephens
    More analyst ratings

    $MRK
    $VEEV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Thulin Inge G bought $250,000 worth of shares (2,833 units at $88.25), increasing direct ownership by 2,833% to 2,933 units (SEC Form 4)

      4 - Merck & Co., Inc. (0000310158) (Issuer)

      2/7/25 4:09:51 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Baker Douglas M Jr bought $1,327,500 worth of shares (15,000 units at $88.50), increasing direct ownership by 1,500% to 16,000 units (SEC Form 4)

      4 - Merck & Co., Inc. (0000310158) (Issuer)

      2/7/25 4:04:52 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRK
    $VEEV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Health Canada Approves KEYTRUDA® for the treatment of adult patients with FIGO 2014 Stage III-IVA cervical cancer, in combination with chemoradiotherapy (CRT)¹

      Approval is based on the results from phase III KEYNOTE-A18/ENGOT-cx11/GOG-30472 KIRKLAND, QC, July 21, 2025 /CNW/ -- Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has granted approval for KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for the treatment of FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer.1,2 The approval is based on data from the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, which demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS) in patients

      7/21/25 11:00:00 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merck Commits to Veeva Vault CRM

      Deep application provides foundation for commercial execution PLEASANTON, Calif., July 21, 2025 /PRNewswire/ -- Veeva Systems (NYSE:VEEV) today announced that Merck (NYSE:MRK), known as MSD outside of the United States and Canada, has committed to Veeva Vault CRM. The Vault CRM solution will support Merck as they enter one of the most significant launch periods in the company's history across a diverse set of new therapeutic areas and modalities. "We are excited to expand our strategic partnership with Veeva by moving to Vault CRM," said Dave Williams, executive vice president

      7/21/25 10:00:00 AM ET
      $MRK
      $VEEV
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Computer Software: Prepackaged Software
      Technology
    • Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill

      In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the initiation of the EXPrESSIVE Phase 3 clinical trials, evaluating the safety and efficacy of MK-8527, an investigational once-monthly, oral nucleoside reverse transcriptase translocation inhibitor (NRTTI) for HIV pre-exposure prophylaxis (PrEP). The EXPrESSIVE-11 (MK-8527-011, NCT 07044297) trial will evaluate the safety and efficacy of MK-8527 among people with greater likelihood of HIV-1 exposure in 16 countries and will begin enrolling in August 2025. In collaboration with t

      7/14/25 9:31:00 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRK
    $VEEV
    SEC Filings

    See more
    • SEC Form 11-K filed by Merck & Company Inc.

      11-K - Merck & Co., Inc. (0000310158) (Filer)

      6/27/25 2:16:51 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by Merck & Company Inc.

      11-K - Merck & Co., Inc. (0000310158) (Filer)

      6/27/25 2:12:30 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by Merck & Company Inc.

      11-K - Merck & Co., Inc. (0000310158) (Filer)

      6/27/25 2:08:51 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRK
    $VEEV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Gen. Counsel, Secretary Faddis Jonathan sold $205,646 worth of shares (720 units at $285.62), decreasing direct ownership by 8% to 7,902 units (SEC Form 4)

      4 - VEEVA SYSTEMS INC (0001393052) (Issuer)

      7/11/25 5:27:16 PM ET
      $VEEV
      Computer Software: Prepackaged Software
      Technology
    • Director Hung Priscilla sold $97,308 worth of shares (343 units at $283.70), decreasing direct ownership by 8% to 3,966 units (SEC Form 4)

      4 - VEEVA SYSTEMS INC (0001393052) (Issuer)

      7/8/25 5:12:49 PM ET
      $VEEV
      Computer Software: Prepackaged Software
      Technology
    • Chief Financial Officer Van Wagener Brian converted options into 872 shares and covered exercise/tax liability with 274 shares, increasing direct ownership by 10% to 6,733 units (SEC Form 4)

      4 - VEEVA SYSTEMS INC (0001393052) (Issuer)

      7/2/25 7:31:15 PM ET
      $VEEV
      Computer Software: Prepackaged Software
      Technology

    $MRK
    $VEEV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham reiterated coverage on Veeva Systems with a new price target

      Needham reiterated coverage of Veeva Systems with a rating of Buy and set a new price target of $300.00 from $270.00 previously

      5/29/25 7:48:02 AM ET
      $VEEV
      Computer Software: Prepackaged Software
      Technology
    • Merck downgraded by Citigroup with a new price target

      Citigroup downgraded Merck from Buy to Neutral and set a new price target of $84.00

      5/14/25 8:57:17 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Merck with a new price target

      Cantor Fitzgerald initiated coverage of Merck with a rating of Neutral and set a new price target of $85.00

      4/22/25 8:01:38 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRK
    $VEEV
    Leadership Updates

    Live Leadership Updates

    See more
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components
    • Ashland Board appoints Sanat Chattopadhyay, executive vice president, Merck & Company, as new director effective November 13, 2023

      WILMINGTON, Del., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) has announced the appointment of Sanat Chattopadhyay, executive vice president of Merck & Company (NYSE:MRK) to its Board of Directors. Chattopadhyay will serve on the Board's Environmental, Health, Safety, and Quality and Governance and Nominating Committees, effective November 13, 2023.  Prior to Merck, Chattopadhyay held leadership positions at Wyeth Pharmaceuticals, Aventis, Hoechst Marion Roussel and Hoechst India. As previously announced, Jay V. Ihlenfeld who has served as a director since 2017, and Brendan M. Cummins, who joined the board in 2012 have decided not to stand for re-election at Ashland's Annua

      11/14/23 5:25:00 PM ET
      $ASH
      $MRK
      Specialty Chemicals
      Consumer Discretionary
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer

      Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer Arun Balakumaran M.D., Ph.D, appointed Chief Medical Officer of Replay to support the Company's genomic medicine and engineered NK cell therapy pipelineFormer Chief Medical Officer of allogeneic CAR-T cell company Allogene Therapeutics and seasoned industry immuno-oncology, and cell and gene therapy expert Dr. Balakumaran also appointed CMO of Syena, Replay's engineered NK cell therapy product company pioneering first-in-class engineered T-cell Receptor Natural Killer cell (TCR-NK) therapy San Diego, California and London, UK, May 18, 2023 – Replay, a genome writing company reprogramming biology by writing and deliver

      5/18/23 8:00:00 AM ET
      $ALLO
      $AMGN
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $MRK
    $VEEV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Veeva Systems Inc. (Amendment)

      SC 13G/A - VEEVA SYSTEMS INC (0001393052) (Subject)

      2/16/24 4:29:43 PM ET
      $VEEV
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G/A filed by Veeva Systems Inc. (Amendment)

      SC 13G/A - VEEVA SYSTEMS INC (0001393052) (Subject)

      2/14/24 3:12:28 PM ET
      $VEEV
      Computer Software: Prepackaged Software
      Technology
    • SEC Form SC 13G/A filed by Veeva Systems Inc. (Amendment)

      SC 13G/A - VEEVA SYSTEMS INC (0001393052) (Subject)

      2/14/24 10:03:02 AM ET
      $VEEV
      Computer Software: Prepackaged Software
      Technology

    $MRK
    $VEEV
    Financials

    Live finance-specific insights

    See more
    • Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call July 29

      Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, July 29. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Fr

      7/1/25 6:45:00 AM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Veeva Announces Fiscal 2026 First Quarter Results

      Total Revenues of $759.0M, up 17% Year Over YearSubscription Services Revenues of $634.8M, up 19% Year Over Year PLEASANTON, Calif., May 28, 2025  /PRNewswire/ -- Veeva Systems Inc. (NYSE:VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its first quarter ended April 30, 2025. "I consider this our best first quarter ever. We executed with speed, quality, and innovation across all areas on short-term objectives and long-term initiatives aligned to our values and 2030 goals," said CEO Peter Gassner. "Thanks t

      5/28/25 4:05:00 PM ET
      $VEEV
      Computer Software: Prepackaged Software
      Technology
    • Merck Announces Third-Quarter 2025 Dividend

      Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company's common stock for the third quarter of 2025. Payment will be made on July 8, 2025, to shareholders of record at the close of business on June 16, 2025. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intens

      5/27/25 1:24:00 PM ET
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care